

available at [www.sciencedirect.com](http://www.sciencedirect.com)journal homepage: [www.ejconline.com](http://www.ejconline.com)

## Corrigendum

# Corrigendum to “Management of toxicity in patients receiving therapy with bevacizumab” [EJC Suppl. 6(6) (2008) 29–39]

David Miles\*

Mount Vernon Hospital, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK

The author regrets that there is an error in Table 2 of the article mentioned above.

Efficacy outcomes from the E2100 study are incorrectly cited as: median PFS (11.4 versus 5.8 months,  $p < 0.0001$ ) response rate (48% versus 23.4%,  $p < 0.0001$ ) and 1-year sur-

vival (81.4% versus 74.0%,  $p = 0.017$ ). The correct data are as follows: median PFS (11.8 versus 5.9 months,  $p < 0.001$ ) response rate (49.2% versus 25.2%,  $p < 0.001$ ) and 1-year survival (81.2% versus 73.4%,  $p = 0.01$ ).

DOI of original article: [10.1016/S1359-6349\(08\)70290-8](https://doi.org/10.1016/S1359-6349(08)70290-8)

\* Address for correspondence: Department of Oncology, University of Leeds, Leeds, UK. Tel.: +44 1923 844291; fax: +44 1923 844840.

E-mail address: [david.miles@doctors.org](mailto:david.miles@doctors.org)

0959-8049/\$ - see front matter © 2008 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2008.07.024